Neil Weir, Sitryx CEO
September 27, 2023 07:36 AM EDTUpdated 08:07 AM
Startups

Big Phar­ma-backed Sit­ryx locks an ad­di­tion­al $39M in a Se­ries A raise to ad­vance its im­munometa­bol­ic pipeline

Ayisha Sharma

News Reporter

Sit­ryx Ther­a­peu­tics has raised an ad­di­tion­al £32 mil­lion ($39 mil­lion) in a fol­low-on to its 2018 Se­ries A to help push its im­munometa­bol­ic pipeline in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times